147699-19-2

Basic information

• Product Name: 1-BOC-4-(2-METHANESULFONYLOXY-ETHYL)-PIPERIDINE
• Synonyms: 1-BOC-4-(2-METHANESULFONYLOXY-ETHYL)-PIPERIDINE;1-N-Boc-4-(2-Methanesulfonyloxyethyl)piperidine;tert-Butyl 4-(2-(methylsulfonyloxy)ethl)piperidine-1-carboxylate;tert-butyl 4-(2-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate;tert-butyl 4-[2-(methanesulfonyloxy)ethyl]piperidine-1-carboxylate
• CAS NO: 147699-19-2
• Molecular Formula: C₁₃H₂₅NO₅S
• Molecular Weight: 307.41
• Mol File: 147699-19-2.mol

Chemical Properties

• Boiling Point: 431.1±18.0 °C(Predicted)
• Appearance: /
• Density: 1.154±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.54±0.40(Predicted)
• CAS DataBase Reference: 1-BOC-4-(2-METHANESULFONYLOXY-ETHYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(2-METHANESULFONYLOXY-ETHYL)-PIPERIDINE(147699-19-2)
• EPA Substance Registry System: 1-BOC-4-(2-METHANESULFONYLOXY-ETHYL)-PIPERIDINE(147699-19-2)

Safety Data

• Hazardous Substances Data: 147699-19-2(Hazardous Substances Data)

Usage

Chemical Structure

A piperidine ring with a BOC (tert-butoxycarbonyl) protective group at the nitrogen atom and a methanesulfonyloxy-ethyl group attached to the piperidine ring.

BOC (tert-butoxycarbonyl)

A protecting group for the nitrogen atom in the piperidine ring.

Methanesulfonyloxy-ethyl

A functional group that can be used for further functionalization of the piperidine ring.

Role of BOC Group

Prevents unwanted reactions at the nitrogen atom by acting as a protective group.

Role of Methanesulfonyloxy-Ethyl Group

Allows for functionalization of the piperidine ring in chemical reactions.

Organic Synthesis

Used as an intermediate in the preparation of various compounds.

Pharmaceutical Industry

Utilized to synthesize bioactive molecules.

Agrochemical Industry

Employed in the synthesis of pesticides.

Importance

Facilitates the synthesis of a wide range of compounds with potential applications in medicine and agriculture.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 34619-03-9 tert-butyldicarbonate 
• 51052-78-9 4-piperidinylacetic acid 
• 124-63-0 methanesulfonyl chloride 
• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 
• 108-20-3 di-isopropyl ether 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 

Downstream Products

• 407623-61-4 4-(4-chlorobenzoyl)-1-[2-(4-piperidinyl)ethyl]-1,3,4,5-tetrahydrobenzo[e][1,4]diazepin-2-on 
• 239072-94-7 4-Benzyloxycarbonyl-1-[2-(1-tert-butoxycarbonyl-4-piperidyl)ethyl]-2-piperazinone 
• 958025-66-6 MPC-3100 
• 1230795-37-5 4-[2-(1-tert-Butyloxycarbonylpiperidin-4-yl)ethyl]-1-(4-ethoxycarbonylmethylaminophenyl)piperazine 
• 1230795-36-4 4-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)ethyl]-1-[3,5-di(ethoxycarbonylmethyloxy)phenyl]piperazine 
• 1230795-34-2 4-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)ethyl]-1-[2,4-di(ethoxycarbonylmethyloxy)phenyl]piperazine 
• 198626-78-7 4-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)ethyl]-1-(4-methoxycarbonylmethyloxyphenyl)-2-methylpiperazine 
• 198626-82-3 4-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)ethyl]-1-(3-ethoxycarbonylmethyloxyphenyl)piperazine 
• 198626-89-0 4-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)ethyl]-1-[4-(N-n-butylsulphonyl-N-methoxycarbonylmethylamino)phenyl]piperazine 
• 198626-86-7 1-[4-(N-acetyl-N-methoxycarbonylmethylamino)phenyl]-4-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)ethyl]piperazine 
• 198626-84-5 4-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)ethyl]-1-(trans-4-methoxycarbonylmethyloxycyclohexyl)piperazin-2-one 
• 198626-80-1 (S)-4-[2-(1-tert-Butyloxycarbonylpiperidin-4-yl)ethyl]-1-(4-ethoxycarbonylmethyloxyphenyl)-3-(4-methoxybenzyl)piperazin-2-one 
• 198626-75-4 4-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)ethyl]-1-[3,4-di(methoxycarbonylmethyloxy)phenyl]piperazine 
• 198626-72-1 4-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)ethyl]-1-[4-(2-methoxycarbonylethyl)phenyl]piperazine 

Relevant articles and documents

A straightforward enantioselective synthesis of F17807

An efficient approach for the enantioselective synthesis of the 1,4-benzodioxane F17807 drug is reported. The developed route relied on two key steps, namely SNAr and Mitsunobu reactions, which permitted a straightforward access to the title co

Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction

The protein-protein interaction between menin and mixed-lineage leukemia 1 (MLL1) plays an important role in development of acute leukemia with translocations of the MLL1 gene and in solid tumors. Here, we report the development of a new generation of menin-MLL1 inhibitors identified by structure-based optimization of the thienopyrimidine class of compounds. This work resulted in compound 28 (MI-1481), which showed very potent inhibition of the menin-MLL1 interaction (IC50 = 3.6 nM), representing the most potent reversible menin-MLL1 inhibitor reported to date. The crystal structure of the menin-28 complex revealed a hydrogen bond with Glu366 and hydrophobic interactions, which contributed to strong inhibitory activity of 28. Compound 28 also demonstrates pronounced activity in MLL leukemia cells and in vivo in MLL leukemia models. Thus, 28 is a valuable menin-MLL1 inhibitor that can be used for potential therapeutic applications and in further studies regarding the role of menin in cancer.

Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors

Herein we envisaged the possibility of exploiting alkyl nitrates as precursors of alcohol-bearing dual inhibitors targeting acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), key enzymes in neurodegenerative syndromes such as Alzheimer's disease (AD), through biotransformation unmasking an alcoholic function upon nitric oxide (NO) release. The cooperation to neuroprotection of low fluxes of NO and target enzymes’ inhibition by the alcohol metabolites might return a multitargeting effect. The in vitro screening towards ChEs and MAOs of a collection of 21 primary alcohols disclosed a subset of dual inhibitors, among which three diverse chemotypes were selected to study the corresponding nitrates. Nitrate 14 proved to be a brain permeant, potent AChE-MAO B inhibitor by itself. Moreover, it protected human SH-SY5Y lines against rotenone and hydrogen peroxide with a poor inherent cytotoxicity and showed a slow conversion profile to its alcohol metabolite 9d that still behaved as bimodal and neuroprotective molecule.

N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES

The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

Piperidine amino derivative and application thereof in fighting schizophrenia

The invention discloses a piperidine amino compound and an application thereof in fighting schizophrenia. Pharmacological experiment results show that the piperidine amino compound related to by the invention has good water solubility, has high affinity with dopamine D, D, 5-HT, and 5-HT receptors, and has good selectivity on D/D receptors. In-vivo test results show that a preferable compound has a good anti-schizophrenia effect, is relatively low in acute toxicity, high in safety and good in pharmacokinetic characteristic, and has a development value as a high-efficiency low-toxicity novel anti-schizophrenia new drug. The piperidine amino compounds are compounds represented as a structural general formula (I), or salts of the compounds, or hydrates of the salts.

NEW ANTI-MALARIAL AGENTS

The present invention is related to new trioxolane derivatives of formula (I) in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to trioxolane derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis

Bruton's tyrosine kinase (Btk) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) and Fcγ receptor (FcR) signaling pathways, which makes it a uniquely attractive target for the treatment of autoimmune diseases, such as rheumatoid arthritis (RA). We reported a series of compounds bearing 7H-pyrrolo [2,3-d]pyrimidin-4-amine scaffold that potently inhibited Btk in vitro. Analysis of the structure-activity relationships (SAR) and drug-like profiles led to the discovery of the optimal compound B16. B16 preferentially inhibited Btk (IC50 = 21.70 ± 0.82 nM) over closely related kinases with moderate selectivity. Cell-based tests also confirmed that B16 significantly inhibited Btk Y223 auto-phosphorylation and PLCγ2 Y1217 phosphorylation. MTT revealed that B16 displayed weak suppression against normal LO2, HEK293 and THP-1 cell lines with IC50 values over 30 μM. Moreover, B16 showed very weak potential to block the hERG channel (IC50 = 11.10 μM) in comparison to ibrutinib (IC50 = 0.97 μM). Owing to its favorable physicochemical properties (ClogP = 2.53, aqueous solubility ≈ 0.1 mg/mL), pharmacokinetic profiles (F = 49.15%, t1/2 = 7.02 h) and reasonable CYP450 profile, B16 exhibited potent anti-arthritis activity and similar efficacy to ibrutinib in reducing paw thickness in CIA mice. In conclusion, B16 is a potent, selective and durable inhibitor of Btk and has the potential to a safe and efficacious treatment for arthritis.

2-(BICYCLO-HETEROARYL)-ISONICOTINIC DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to compounds of Formula (I) as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

With anti-platelet aggregation activity of the piperidinyl substituted 5- hydroxy color acid derivatives

The invention relates to the field of pharmaceutical chemistry, particularly piperidyl substituted 5-hydroxytryptophane derivatives (I) with anti-platelet aggregation activity, and a preparation method and pharmaceutical application thereof, wherein R1, R2 and n are defined in the specification. The pharmacodynamical test proves that the piperidyl substituted 5-hydroxytryptophane derivatives have favorable anti-platelet aggregation activity.

Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics

A series of novel benzisothiazolylpiperazine derivatives combining potent dopamine D2and D3, and serotonin 5-HT1Aand 5-HT2Areceptor properties were synthesized and evaluated for their potential antipsychotic properties. The most-promising derivative was 9j. The unique pharmacological features of 9j were a high affinity for D2, D3, 5-HT1A, and 5-HT2Areceptors, together with a 20-fold selectivity for the D3versus D2subtype, and a low affinity for muscarinic M1(reducing the risk of anticholinergic side effects), and for hERG channels (reducing incidence of QT interval prolongation). In animal behavioral models, 9j inhibited the locomotor-stimulating effects of phencyclidine, blocked conditioned avoidance response, and improved the cognitive deficit in the novel object recognition tests in rats. 9j exhibited a low potential for catalepsy, consistent with results with risperidone. In addition, favorable brain penetration of 9j in rats was detected. These studies have demonstrated that 9j is a potential atypical antipsychotic candidate.